Viewing Study NCT07287202

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:38 AM
Ignite Modification Date: 2025-12-26 @ 2:22 AM
Study NCT ID: NCT07287202
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-23
First Post: 2025-12-11
Is NOT Gene Therapy: False
Has Adverse Events: False
Brief Title: Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
Sponsor: SoVarGen Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Focal Cortical Dysplasia View
None Tuberous Sclerosis Complex (TSC) View
None Hemimegalencephaly View
Keywords:

Keywords

Keyword Brief Keyword Text View
None FCD-II View
None TSC View
None HME View